Guidelines International Network | Guidelines International Network (GIN)

Urinesteenlijden (M63)

MeSH Terms: Genital Diseases; Male (C12.294); Urologic Diseases (C12.777); Urinary Tract Infections (C12.777.892)
Guideline Contact: Jolanda Wittenberg ([email protected])
English Title Translation: Urinary tract infection
Publication Scope: assessment; management
Countries of Application: Netherlands
Guideline Publication Status: Published
Languages: Dutch
Authors: NHG (NL)
Publication Year: 2025

MeSH Terms: Female Genital Diseases and Pregnancy Complications (C13); Patient Care (N02.421.585); Urologic and Male Genital Diseases (C12); Palliative Care (N02.421.585.666); Urethral Diseases (C12.777.767); Urinary Tract Infections (C12.777.892); Urination Disorders (C12.777.934); Urinary Incontinence (C12.777.934.852)
English Title Translation: Urogenital problems
Publication Scope: assessment; management
Countries of Application: Netherlands
Guideline Publication Status: Published
Languages: Dutch
Authors: IKNL (NL)
Publication Year: 2010

MeSH Terms: Urolithiasis (C13.351.968.967); Urolithiasis (C12.777.967)
Guideline Contact: Ministry of Public Health ([email protected])
Date for Review: 31/12/2018
Publication Scope: assessment; counselling; management; patient_education; prevention; prognosis; rehabilitation; treatment
Countries of Application: Qatar
Guideline Publication Status: Published
Languages: English
Authors: MOPH QA Ministry of Public Health/Qatar
Publication Year: 2016

MeSH Terms: Bladder Neoplasms (C04.588.945.947.125); Cancer / Neoplasms (C04); Urologic and Male Genital Diseases (C12); Urogenital Neoplasms (C04.588.945)
English Title Translation: Bladder concer
Publication Scope: management
Countries of Application: Netherlands
Guideline Publication Status: Published
Languages: Dutch
Authors: IKNL (NL)
Publication Year: 2009

MeSH Terms: Breast Neoplasms, breast tumor, breast cancer, breast neoplasm, Diphosphonates, bisphosphonic acid derivative, bisphosphonate, zoledron, ibandron, pamidron, risedron, alendron, neridron, olpadron, clodron, tiludron, etidron, reclast, zometa, aclasta, boniva, aredia, actonel, fosamax, nerixia, bonefos, loron, skelid, didronel, Bone Density Conservation Agents, Endothelin A Receptor Antagonists, denosumab, calcitonin, dasatinib, rilotumumab, cabozantinib, bone-modifying agent, atrasentan, zibotentan, dasatinib, rilotumumab, AMG102, cabozantinib, Prolia, Xgeva, Fortical, Miacalicin, Evista
Guideline Contact: Glenn Fletcher; [email protected]
Keywords: breast neoplasms, breast cancer, diphosphonates, bisphosphonate, bone-modifying agent, adjuvant therapy
Date for Review: In Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario), we have an annual review process for each guideline after it is completed. Guidelines are reviewed every fall after they are older than 1 year.
Publication Date: 2022-07-14
Date of Last Evidence Search: 2021-01-28
Methods Applied: Evidence-based, Systematic review-based, Externally reviewed, Evidence quality assessmen
Publication Scope: Guidelines; treatment
Countries of Application: Canada
Guideline Publication Status: Published
Languages: English
Authors: PEBC (Program in evidenced-based care)
Publication Year: 2022

MeSH Terms: Breast Neoplasms (C04.588.180); Biomarkers; Pharmacological (D23.101.137); Neoplasms (C04)
Guideline Contact: [email protected]
Publication Date: 31-May-19
Publication Scope: treatment
Countries of Application: United States
Guideline Publication Status: Published
Languages: English
Authors: ASCO (US)
Publication Year: 2019